Skip to main content
Clinical Trials/NCT05374200
NCT05374200
Completed
N/A

A Randomized Control Trial Evaluating the Impact of a 12-week Mind-body Wellness Intervention in Patients With Primary Biliary Cholangitis (PBC)

University of Alberta1 site in 1 country87 target enrollmentOctober 3, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Primary Biliary Cirrhosis
Sponsor
University of Alberta
Enrollment
87
Locations
1
Primary Endpoint
HADS Anxiety and Depression Scale
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The investigators have designed a guided, online, multicomponent, mind-body intervention for participants with primary biliary cholangitis. The ability of the online intervention to impact the primary and secondary outcome measures will be assessed as compared to control.

Detailed Description

Persons with primary biliary cholangitis (PBC) experience significantly higher rates of fatigue, stress, anxiety, depression, and impaired health related quality of life (HRQOL) as compared to the general population. Online wellness programming ranging from physical activity to mindfulness interventions has been shown to be effective in decreasing fatigue and improving mental wellness in a variety of chronic disease populations. To date, no large-scale studies have been conducted to discern whether programming of this nature impacts measures of wellbeing in PBC. Building upon a 12-week, online, mind-body wellness program that our team previously co-developed with the Canadian PBC Society and launched as a feasibility and acceptability trial to a group of 30 individuals with PBC, the primary aim of this research project is to carry out a randomized controlled trial to assess the efficacy of the online intervention provided with brief study follow-up phone calls performed weekly by study personnel as compared to a control arm. The ability of the online program to impact the primary outcome measure of anxiety and depression as measured by the hospital anxiety and depression scale (HADS), and a range of secondary outcomes including perceived stress, fatigue, resilience, health related quality of life, physical functioning will be assessed as compared to control.

Registry
clinicaltrials.gov
Start Date
October 3, 2021
End Date
April 9, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults (≥ 18 years)
  • Identified diagnosis of PBC
  • Ability to communicate (read, write, speak) in English
  • Access to an internet connected device at home.

Exclusion Criteria

  • Inability to provide informed consent
  • Unsafe to participate in a low-intensity online activity program (e.g. uncontrolled angina or arrhythmia, myocardial infarction or stroke within the last 3 month, other major medical comorbidity of concern)
  • Severe psychiatric disorders (HADS score \>10)

Outcomes

Primary Outcomes

HADS Anxiety and Depression Scale

Time Frame: Baseline to 12 weeks

Depression and anxiety will be measured on the Hospital Anxiety and Depression Scale. The minimum score is 0, the maximum score is 21, and higher scores indicate a worse outcome.

Secondary Outcomes

  • PBC-40(Baseline to 12 weeks)
  • Connor Davidson Resilience Scale 10(12 Weeks)
  • Perceived Stress Scale(12 Weeks)
  • Modified Fatigue Impact Scale(12 Weeks)
  • Lower Extremity Function Scale(12 Weeks)
  • Capability, Opportunity, Motivation, Behavior (COM-B) Survey(12 Weeks)

Study Sites (1)

Loading locations...

Similar Trials